Chester County News and Community Website
PHILADELPHIA, PA — Aro Biotherapeutics has appointed biotechnology executive Brett Blackman to its board as the clinical-stage company seeks to expand its targeted short-interfering RNA platform into additional disease areas …
Aro Adds Biotech Executive as siRNA Platform Expands Read More
PHILADELPHIA, PA — Aro Biotherapeutics announced positive topline results from the Phase 1b portion of a clinical trial evaluating its investigational therapy ABX1100 for late-onset Pompe disease, showing reductions in …
Aro Biotherapeutics Reports Positive Phase 1b Data for Pompe Therapy Read More
PHILADELPHIA, PA — Aro Biotherapeutics reported interim data from a Phase 1b study of ABX1100, an investigational therapy for late-onset Pompe disease, showing the drug was generally well tolerated and …
Experimental Pompe Therapy Shows Early Promise in Trial Read More PHILADELPHIA, PA — Aro Biotherapeutics said it will present interim clinical data next month from its ongoing Phase 1b trial of ABX1100, an experimental therapy aimed at treating late-onset Pompe …
Experimental Pompe Therapy Shows Early Signal Ahead of Key San Diego Reveal Read More PHILADELPHIA, PA — Aro Biotherapeutics announced it has completed enrollment in its Phase 1b clinical trial of ABX1100, an investigational therapy for late-onset Pompe disease (LOPD). The study is designed …
Aro Biotherapeutics Completes Enrollment in Pompe Disease Trial for ABX1100 Read More